On the Record · Lakefront Biotherapeutics
Lakefront Biotherapeutics competitors, on the record
The companies Lakefront Biotherapeutics itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Lakefront Biotherapeutics names
| Company | Named in |
|---|---|
| Abbvie | 2025 |
| Argenx | 2025 |
| AstraZeneca | 2025 |
| BMS | 2025 |
| Idorsia/Viatris | 2025 |
| Pfizer | 2025 |
In its own words
Abbvie, BMS, Idorsia/Viatris
Word for word“There remains a minority of oral therapies, under development – most notably deucravacitinib (Sotyktu TM ) (TYK2) from BMS, upadacitinib (Rinvoq TM ) (JAK) from Abbvie and cenerimod (S1P1) from Idorsia/Viatris.” 20-F for 2025
Argenx, AstraZeneca, Pfizer
Word for word“Additionally, there are a number of Phase 3 compounds (dazukibart (anti-IFN; Pfizer), anifrolumab (Saphnelo®; anti-IFN; AstraZeneca) and efartigimod (Vyvgart®; anti-FcRn; Argenx) which could launch before the end of the decade.” 20-F for 2025
Read from Lakefront Biotherapeutics’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.